With its launch of chronic myeloid leukemia drug Iclusig, Ariad Pharmaceuticals just topped Wall Street estimates for the quarter and is showing significant promise despite what on the surface appear to be meager numbers.

In this video, health-care analyst David Williamson discusses its potential to continue to surprise investors and beat Wall Street going forward. Watch and find out if Ariad is a stock investors need on their radars.

Follow David on Twitter: @MotleyDavid.

David Williamson and The Motley Fool have no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.